eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
3/2010
vol. 35
 
Share:
Share:
abstract:

Experimental immunology
High-dose methotrexate ameliorates collagen-induced arthritis but does not inhibit the release of proinflammatory cytokines by peritoneal macrophages in mice

Bernadeta Nowak
,
Piotr Głuszko
,
Marta Ciszek-Lenda
,
Małgorzata Śróttek
,
Beata Kwaśny-Krochin
,
Janusz Marcinkiewicz

(Centr Eur J Immunol 2010; 35 (3): 128-137)
Online publish date: 2010/10/05
View full text Get citation
 
Methotrexate (MTX) is used in the treatment of rheumatoid arthritis (RA) due to its anti-inflammatory properties. However, its ability to suppress macrophage derived proinflammatory cytokines has not been explained. The aim of this study was to compare the therapeutic effects of high-dose MTX on the development of collagen-induced arthritis (CIA) High-dose MTX reduced significantly both the incidence/severity of CIA and the serum levels of IgG anti-CII. Surprisingly, macrophages obtained from MTX-treated mice and stimulated in vitro with LPS produced more TNF-, IL-6 and IL-12p40 than the control cells. MTX added in vitro to peritoneal macrophages did not affect the cytokine production. However, incubation of proliferating RAW 264.7 macrophages with MTX resulted in severe suppression of all proinflammatory cytokines tested. In conclusion MTX treatment markedly ameliorates arthritis while it does not suppress the cytokine release from peritoneal macrophages. In vitro study indicates that MTX can inhibit the cytokine production if target cells proliferate.
keywords:

methotrexate (MTX), collagen induced arthritis (CIA), macrophages, cytokines

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.